POLIVY is composed of the potent cytotoxin monomethyl auristatin E (MMAE) and a CD79b-targeted monoclonal antibody (mAb) 1,3-5

A CD79b-directed regimen may offer an urgently needed option for treating patients in the third line or greater 6,7

  • Patients who have insufficient response to second-line treatment have a poor prognosis 6
  • Historically, only about 26% of patients refractory to second-line or greater therapy have a response, with a median overall survival of 6.1 months 7*

*SCHOLAR-1 was an international, multi-cohort study that retrospectively evaluated responses and overall survival rates in 636 patients with refractory DLBCL. 7

Proposed mechanism of action (MOA) 1

POLIVY binds to the CD79b portion of the B-cell receptor complex on B cells, triggering internalization of POLIVY and the receptor complex.

Once internalized, the stable linker is cleaved, releasing MMAE within the B cell.

MMAE binds to microtubules and kills dividing cells by inhibiting cell division and inducing apoptosis.

Apoptosis of malignant B cell occurs.

See the POLIVY proposed MOA in action